Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 31
- Registration Number
- NCT02243098
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia BHaemophilia B With InhibitorsRelatives to/Carers of PatientsHaemophilia A With InhibitorsHaemophilia A
- Interventions
- Other: No treatment given
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT02241694
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Phase 1
Completed
- Conditions
- Acquired Bleeding DisorderCardiac Surgery Requiring Cardiopulmonary Bypass
- Interventions
- Drug: placebo
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 43
- Registration Number
- NCT02239146
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 163
- Registration Number
- NCT02235961
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT02231684
A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 704
- Registration Number
- NCT02230631
Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1029
- Registration Number
- NCT02230618
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Thriruvananthapuram, India
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
Phase 3
Completed
- Conditions
- Adult Growth Hormone DeficiencyGrowth Hormone Disorder
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 301
- Registration Number
- NCT02229851
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1HealthyDiabetes
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT02220296
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 87
- Registration Number
- NCT02212067
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
© Copyright 2025. All Rights Reserved by MedPath